Literature DB >> 7076796

Thyrotropin binding and adenylate cyclase activation in normal and neoplastic human thyroid tissue: lack of effect of thyroglobulin.

O H Clark, P L Gerend, R A Nissenson.   

Abstract

The effects of bovine TSH (bTSH) and bovine (bTg) and human thyroglobulin (hTg) on the binding of [125I] bTSH and the activation of adenylate cyclase (AC) were studied in both normal and neoplastic human thyroid homogenates in vitro using adenylate cyclase conditions. [125I]bTSH bound specifically and with high affinity to a particulate fraction from normal thyroid and from benign and malignant thyroid neoplasms; this binding was inhibited by unlabeled bTSH (approximate Kd = 10.0 mU/ml for normal tissue; Kd = 2.5 mU/ml for thyroid neoplasms). Half-maximal activation of AC was obtained at a TSH concentration of approximately 2.5 mU/ml for both normal and neoplastic thyroid tissue, indicating that the high affinity TSH receptors are coupled to AC, at least in the neoplastic thyroid tissue. bTg and hTg did not inhibit [125I]bTSH binding to high affinity TSH receptors in either normal or neoplastic thyroid tissue. bTSH increased AC activity up to 25-fold in neoplastic thyroid tissue and up to 4-fold in normal thyroid tissue, whereas at concentrations up to 1 mg/ml, bTg had no effect. The current study demonstrates that bTSH binds to specific, high affinity receptors and stimulates AC activity in both normal and neoplastic thyroid tissue. bTg and hTg, under the conditions used in this experiment, do not influence TSH binding to its high affinity receptor in these tissues. Since Tg does not influence high affinity TSH binding or AC activity in a particulate fraction rich in plasma membranes from normal or neoplastic thyroid tissue, it is unlikely to have a modulating role on TSH action at the thyroid plasma membrane.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7076796     DOI: 10.1210/jcem-54-6-1157

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Adenylate cyclase activity as a predictor of thyroid tumor aggressiveness.

Authors:  A E Siperstein; Q H Zeng; E T Gum; K E Levin; O H Clark
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

2.  Mechanisms for increased adenylate cyclase responsiveness to TSH in neoplastic human thyroid tissue.

Authors:  O H Clark; P L Gerend; R A Nissenson
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

3.  Aberrations of growth factor control in metastatic follicular thyroid cancer in vitro.

Authors:  T Hoelting; A Zielke; A E Siperstein; O H Clark; Q Y Duh
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

4.  Epidermal growth factor receptors and adenylate cyclase activity in human thyroid tissues.

Authors:  Q Y Duh; A E Siperstein; R A Miller; J J Sancho; M J Demeure; O H Clark
Journal:  World J Surg       Date:  1990 May-Jun       Impact factor: 3.352

5.  10 years experience with consecutive measurement of thyrotropin binding inhibiting antibodies (TBIAb).

Authors:  J Hensen; P Kotulla; R Finke; K Badenhoop; K Koppenhagen; H Meinhold; H Schleusener
Journal:  J Endocrinol Invest       Date:  1984-06       Impact factor: 4.256

6.  Diminished expression of the alpha 5 beta 1 integrin (fibronectin receptor) by invasive clones of a human follicular thyroid cancer cell line.

Authors:  M J Demeure; K M Doffek; M Rezaee; P E Goretzki; S D Wilson
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.